Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
|||
| Line 38: | Line 38: | ||
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
|Mifepristone | |Mifepristone | ||
| − | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of FFS |
|- | |- | ||
|} | |} | ||
Revision as of 19:16, 11 November 2019
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
Unresectable, all lines of therapy
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | Phase III (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed